PTLA hopes they can get FDA approval for PRT-4445 based a single 100-200-patient PD study and that efficacy studies in bleeding patients can be done on a post-marketing basis. I think they’re dreaming.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”